These findings support a model in which CIP2A overexpression drives metabolic reprogramming in lung cancer through dual modulation of the AKT–AMPK axis, consistent with our observation of reduced p-AMPK and elevated p-AKT in CIP2A-high tumors. The gene discussed is AKT1; the disease is lung carcinoma.